Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/11986
Title: Anti-angiogenic and anti-proliferative effects of benja-ummarit extract in rats with hepatocellular carcinoma
Authors: Kaewnoonual N.
Itharat A.
Pongsawat S.
Nilbu-Nga C.
Kerdput V.
Pradidarcheep W.
Keywords: 2' para methoxycoumaroylaloeresin
5 hydroxyaloin A
alanine aminotransferase
albumin
alkaloid
aloeresin B derivative
aloesin
aloin
angiogenesis inhibitor
antimitotic agent
benja ummarit extract
biochemical marker
dehydropipernoline
diethylnitrosamine
dihydrogambogic acid derivative
gambogic acid
pipercide
piperettine
pipericine
piperine
plant extract
sorafenib
thioacetamide
unclassified drug
vasculotropin
alanine aminotransferase blood level
albumin blood level
animal experiment
animal model
animal tissue
antiangiogenic activity
antiproliferative activity
Article
blood sampling
body weight
cancer growth
chemical composition
comparative study
controlled study
down regulation
drug efficacy
herbal medicine
histopathology
in vivo study
liquid chromatography-mass spectrometry
liver cell carcinoma
liver function test
liver histology
liver injury
liver tissue
liver weight
male
nonhuman
protein expression
rat
real time reverse transcription polymerase chain reaction
tumor vascularization
Western blotting
Issue Date: 2020
Abstract: The herbal extract Benja-ummarit (BU) is a traditional Thai medicine with a putative cancer-suppressing effect. However, this effect has only been tested in vitro in human hepatocarcinoma cell lines. The present study determined the efficacy of a BU extract to treat hepatocellular carcinoma (HCC) in rats in vivo and established its anti-angiogenic and anti-proliferative properties. The BU extract was prepared in 95% ethanol and its composition determined using liquid chromatography-mass spectrometry. HCC was induced in Wistar rats by an injection of diethylnitrosamine (DEN), followed 2 weeks later by injections of thioacetamide (TAA) thrice weekly for 4 weeks. Following 2 months, the DEN-TAA-treated rats were divided into 6 groups that were treated orally for another 2 months with: i) No treatment; ii) vehicle; iii) 30 mg/kg sorafenib (SF); iv) 1 mg/kg BU; v) 10 mg/kg BU; or vi) 50 mg/kg BU. Liver samples were collected for gross morphological, histological, reverse transcription-quantitative PCR and western blot analyses, and serum samples were collected for liver function tests. The size and number of the cancer nodules were reduced ~10-fold in BU-treated HCC groups and ~14-fold in the SF-treated group compared with the HCC group. Furthermore, the serum parameters of liver damage were lower in BU-compared with SF-treated rats. These results indicate that while each of these formulations strongly reduce HCC expansion, BU extract results in less liver damage. Vascular endothelial growth factor expression was reduced significantly in the BU-and SF-treated HCC groups compared with the HCC group (P<0.05). BU extract antagonizes HCC growth in vivo potently through inhibiting tumor angiogenesis. BU, therefore, qualifies as a promising medical herb requiring further evaluation as a treatment of HCC. © 2020, Spandidos Publications. All rights reserved.
URI: https://ir.swu.ac.th/jspui/handle/123456789/11986
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081572598&doi=10.3892%2fbr.2020.1272&partnerID=40&md5=59e8d295718b84e9add10eae87708a1d
ISSN: 20499434
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.